Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report

被引：104

作者：

Goldman, Stanton ^{[1
]}

Smith, Lynette ^{[2
]}

Galardy, Paul ^{[3
]}

Perkins, Sherrie L. ^{[4
]}

Frazer, John Kimble ^{[5
]}

Sanger, Warren ^{[6
]}

Anderson, James R. ^{[2
]}

Gross, Thomas G. ^{[7
]}

Weinstein, Howard ^{[8
]}

Harrison, Lauren ^{[9
]}

Shiramizu, Bruce ^{[10
]}

Barth, Matthew ^{[11
]}

Cairo, Mitchell S. ^{[9
,12
,13
,14
,15
]}

机构：

[1] Med City Childrens Hosp, Div Pediat Hematol Oncol, Dallas, TX USA

[2] Univ Nebraska, Coll Publ Hlth, Dept Biostat, Omaha, NE 68182 USA

[3] Mayo Clin, Dept Pediat Hematol Oncol, Rochester, MN USA

[4] Univ Utah, Dept Pathol, Salt Lake City, UT USA

[5] Univ Oklahoma, Hlth Sci Ctr, Sect Pediat Hematol Oncol, Oklahoma City, OK USA

[6] Univ Nebraska, Ctr Human Genet, Omaha, NE 68182 USA

[7] NCI, Ctr Global Hlth, NIH, Rockville, MD USA

[8] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pediat Hematol Oncol, Boston, MA USA

[9] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA

[10] Univ Hawaii, Div Pediat Hematol Oncol, Honolulu, HI 96822 USA

[11] Roswell Pk Canc Inst, Dept Pediat, Buffalo, NY 14263 USA

[12] New York Med Coll, Dept Med, Valhalla, NY 10595 USA

[13] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA

[14] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA

[15] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 167卷 / 03期

基金：

美国国家卫生研究院;

关键词：

children; Burkitt lymphoma; Burkitt leukaemia; chemotherapy; rituximab; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; ACUTE-LYMPHOBLASTIC-LEUKEMIA; PLUS RITUXIMAB; ADULT BURKITT; CODOX-M/IVAC; PHASE-II; RISK; INTERMEDIATE; THERAPY;

D O I：

10.1111/bjh.13040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375mg/m(2)) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease +/- leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy +/- rituximab for high-risk patients is currently under investigation.

引用

页码：394 / 401

页数：8

共 22 条

[1] Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis [J].

Barnes, J. A. ;

LaCasce, A. S. ;

Feng, Y. ;

Toomey, C. E. ;

Neuberg, D. ;

Michaelson, J. S. ;

Hochberg, E. P. ;

Abramson, J. S. .

ANNALS OF ONCOLOGY, 2011, 22 (08) :1859-1864

[2] Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report [J].

Barth, Matthew J. ;

Goldman, Stanton ;

Smith, Lynette ;

Perkins, Sherrie ;

Shiramizu, Bruce ;

Gross, Thomas G. ;

Harrison, Lauren ;

Sanger, Warren ;

Geyer, Mark B. ;

Giulino-Roth, Lisa ;

Cairo, Mitchell S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) :678-683

[3] Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents [J].

Cairo, Mitchell S. ;

Gerrard, Mary ;

Sposto, Richard ;

Auperin, Anne ;

Pinkerton, C. Ross ;

Michon, Jean ;

Weston, Claire ;

Perkins, Sherrie L. ;

Raphael, Martine ;

McCarthy, Keith ;

Patte, Catherine .

BLOOD, 2007, 109 (07) :2736-2743

[4] Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study [J].

Cairo, Mitchell S. ;

Sposto, Richard ;

Gerrard, Mary ;

Auperin, Anne ;

Goldman, Stanton C. ;

Harrison, Lauren ;

Pinkerton, Ross ;

Raphael, Martine ;

McCarthy, Keith ;

Perkins, Sherrie L. ;

Patte, Catherine .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) :387-393

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma [J].

Corazzelli, Gaetano ;

Frigeri, Ferdinando ;

Russo, Filippo ;

Frairia, Chiara ;

Arcamone, Manuela ;

Esposito, Gennaro ;

De Chiara, Annarosaria ;

Morelli, Emanuela ;

Capobianco, Gaetana ;

Becchimanzi, Cristina ;

Volzone, Francesco ;

Saggese, Mariangela ;

Marcacci, Giampaolo ;

De Filippi, Rosaria ;

Vitolo, Umberto ;

Pinto, Antonio .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (02) :234-244

[7] Low-Intensity Therapy in Adults with Burkitt's Lymphoma [J].

Dunleavy, Kieron ;

Pittaluga, Stefania ;

Shovlin, Margaret ;

Steinberg, Seth M. ;

Cole, Diane ;

Grant, Cliona ;

Widemann, Brigitte ;

Staudt, Louis M. ;

Jaffe, Elaine S. ;

Little, Richard F. ;

Wilson, Wyndham H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20) :1915-1925

[8] A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response [J].

Foran, JM ;

Gupta, RK ;

Cunningham, D ;

Popescu, RA ;

Goldstone, AH ;

Sweetenham, JW ;

Pettengell, R ;

Johnson, PWM ;

Bessell, E ;

Hancock, B ;

Summers, K ;

Hughes, J ;

Rohatiner, AZS ;

Lister, TA .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :81-88

[9] Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report [J].

Galardy, Paul J. ;

Hochberg, Jessica ;

Perkins, Sherrie L. ;

Harrison, Lauren ;

Goldman, Stanton ;

Cairo, Mitchell S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (03) :365-372

[10] Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report [J].

Goldman, S. ;

Smith, L. ;

Anderson, J. R. ;

Perkins, S. ;

Harrison, L. ;

Geyer, M. B. ;

Gross, T. G. ;

Weinstein, H. ;

Bergeron, S. ;

Shiramizu, B. ;

Sanger, W. ;

Barth, M. ;

Zhi, J. ;

Cairo, M. S. .

LEUKEMIA, 2013, 27 (05) :1174-1177

← 1 2 3 →